

● 招待講演

「血管」を鍛えると
超健康になる!

池谷 敏郎

いけたに としろう

医療法人社団池谷医院 院長
東京医科大学 客員講師

※WEB配信はありません。



● 指定演目

Covid-19 に対するプラセンタ
療法の医療的知見
について

長瀬 眞彦

ながせ まひこ

吉祥寺中医クリニック 院長



脳の衰えが気になった時に
効く話

菅原 道仁

すがわら みちひと

菅原脳神経外科クリニック
菅原クリニック 東京脳ドック
理事長



Russian experience of Laennec administration in patients after
COVID-19

Dr. Olga Gromova

オルガ・グロモヴァ

Doctor of Medical
Sciences, Professor, Russia



Dr. Alexander Chuchalin

アレクサンドル・チュチャーリン

Doctor of Medicine, Professor,
Scientist of the Russian
Academy of Sciences



女性が更年期以降を幸年期と
するために

宗田 聡

そうだ さとし

広尾レディース 院長
東京慈恵会医科大学産婦人科
非常勤講師



痛みとプラセンタ

松岡 修平

まつおか しゅうへい

医療法人養生会
松岡医院 院長



防病・健身養生の
中医薬膳

中條 明子

なかじょう あきこ

国際薬膳調理師



ランチョンセミナー 協賛：株式会社ウェルハート

海外の未承認医薬品の扱いに伴う
薬監証明とは

—患者に処方する際の医師の責任、
増加する偽薬と医師のリスク—

今福 吉和 いまふく よしかず

株式会社ウェルハート 代表取締役
厚生労働省 偽造医薬品・指定薬物対策推進会議 民間委員

Russian experience of Laennec administration in patients after COVID-19

産科：長瀬 眞彦 吉祥寺クリニック・院長

The Laennec preparation produced from a standardized hydrolyzate of placenta has been used for many years as an effective and safe hepatoprotector. However, the molecular composition of Laennec, which includes numerous peptide fragments of placental proteins, suggests much wider a range of clinical applications of this drug. In particular, studies of the peptide composition of Laennec, conducted using hybrid proteomic technologies and modern procedures of data analysis, indicated a high regenerative potential of the drug. The data available from experimental and clinical studies show that the regenerative effect of the drug is very broad and by no means limited to the regeneration of the liver parenchyma. The regenerative effect of Laennec has been shown in cut wound/burn models and in patients treated after severe post-traumatic and burn scars of the skin. The use of Laennec as part of complex therapy led to an improvement in the morphological structure of the skin in the area of damage and to a noticeable aesthetic effect (disappearance of the scarring and complete healing of the skin). Experimental and clinical studies have demonstrated the effectiveness of Laennec in the treatment of porphyrin skin aging. On the model of liver hemosiderosis (iron sulfate overload) Laennec contributed to the elimination of hemosiderosis and restoration of the normal liver parenchyma. Clinical studies have confirmed the effectiveness of Laennec in the treatment of hemosiderosis, hyperferritinemia and fatty liver disease. The regenerative effect of Laennec has been shown in a model of adrenaline myocardial damage in rats; a promising application of Laennec is to treat endotheliopathy. In a clinical study of women with underdeveloped endometrium preparing for IVF/ICSI procedures, Laennec contributed to the restoration of sufficient endometrial height without hyperproliferation and, subsequently, to successful pregnancy. The regenerative effects of Laennec in patients with severe course of COVID-19 were manifested as hepatoprotection (decrease in excessive levels of AST and ALT), a decrease in hyperferritinemia, and a decrease in the area of lung damage according to CT. An indirect confirmation of the general regenerative properties of Laennec is a significant (1.5-3 times) increase in the lifespan of *C.elegans* model animals under conditions of thermal or toxic stress. Studies of the composition of Laennec made it possible to identify peptides that determine the regenerative properties of the drug.

指定演題 3

Doctor of Medical Sciences, Professor, Academic of the Russian Academy of Sciences.

Alexander Chuchalin (アレクサンドル・チュチャーリン)

Education :

1963 Pirogov Russian National Research Medical University, Moscow, Russia
 1963-1965 Clinical residency
 1965-1967 Post-graduate courses
 1967 Candidate thesis
 1974 Doctoral thesis, Chairman of the department of hospital therapy at the Pirogov Russian National Research Medical University
 1982 Corresponding member of the USSR Academy of Medical Sciences (Russian Academy of Sciences)
 1987-1990 Vice-president of the USSR Academy of Medical Sciences
 1990 Chuchalin founded Research Institute of Pulmonology
 2003 First Russian winner of the Golden Hippocrates international prize.
 2006 The Order "For Merit to the Fatherland"



指定演題 4

Doctor of Medical Sciences, Professor, Scientific Supervisor of the Institute of Pharmacoinformatics (PIC IU of Russian Academy of Sciences)

Ojga Gromova (オシガ・グロモヴァ)

Education :

1984 Ivanovo State Medical Academy, Ivanovo, Russia
 1984-1987 Assistant of the Department of Pharmacology, IvGMA, Ivanovo
 1988-1992 PhD in Clinical Pharmacology, St. Petersburg Medical University, St. Petersburg
 1992 PhD thesis in Clinical Pharmacology
 1992-2003 Associate Professor of the Department of Pharmacology
 2000 Doctoral thesis in Clinical Pharmacology
 2003 Professor of Clinical Pharmacology
 2017 Scientific Supervisor of the Institute of Pharmacoinformatics of the Federal Research Center for Informatics and Management of the Russian Academy of Sciences.

